Cema-cel also has breakthrough therapy designation for 3rd line r/r LBCL. This was all public information prior to the licensing of Azer-cel. 3rd line treatment is obviously not a large market, so they have attacked front-line consolidation. Very smart commercialization strategy utilizing the advantages of allogeneic.
You are also correct re patient recruitment numbers and timelines, Bav. Nice work.
https://crisprmedicinenews.com/news/allogene-therapeutics-activates-first-clinical-sites-for-pivotal-phase-2-trial-of-cema-cel/#:~:text=In%20June%202022%2C%20the%20FDA,LBCL%20launched%20in%20June%202024.
- Forums
- ASX - By Stock
- IMU
- Media Thread
IMU
imugene limited
Add to My Watchlist
0.00%
!
1.1¢

Media Thread, page-17925
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
1.1¢ |
Change
0.000(0.00%) |
Mkt cap ! $82.13M |
Open | High | Low | Value | Volume |
1.1¢ | 1.2¢ | 1.1¢ | $232.6K | 21.12M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
14 | 9092611 | 1.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
1.2¢ | 11109407 | 47 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
14 | 9092611 | 0.011 |
111 | 28179836 | 0.010 |
36 | 15158780 | 0.009 |
12 | 3890622 | 0.008 |
7 | 3365713 | 0.007 |
Price($) | Vol. | No. |
---|---|---|
0.012 | 11109407 | 47 |
0.013 | 8067839 | 25 |
0.014 | 8452051 | 33 |
0.015 | 8134214 | 29 |
0.016 | 6745871 | 28 |
Last trade - 12.30pm 26/06/2025 (20 minute delay) ? |
Featured News
IMU (ASX) Chart |
The Watchlist
3DA
AMAERO LTD
Hank Holland, Chairman & CEO
Hank Holland
Chairman & CEO
Previous Video
Next Video
SPONSORED BY The Market Online